Melanoma Research Areas Involving NZ Researchers:
Melanoma and Behavioural Research
Professor Louise Signal, Professor Nick Wilson, Professor Ann Richardson, Mrs Bronwyn McNoe, Associate Professor Tony Reeder,
Melanoma Biology
Dist Professor Bruce Baguley, Professor Cris Print, Professor Rod Dunbar, Dr Hilary Sheppard, Professor Mike Berridge, Dr Melanie McConnell, Professor Ian Hermans, Dr Martina Paumann-Page, Professor Antony Braithwaite, Dr Aniruddha Chatterjee, Professor Mike Eccles, Dr Erin Macaulay, Dr Euan Rodger, Dr Adele Woolley,
Melanoma bioinformatic analysis: Dr Peter Stockwell, Associate Professor Mik Black
Molecular profiling predicting outcome: in stage III, Professor Parry Guilford,
Markers of invasive potential: Associate Professor Joel Tyndall
Immune profiling and vaccine development: Associate Professor Rosyln Kemp; Vaccine delivery systems: Professor Sarah Hook; Dendritic cell immunotherapy: Associate Professor Rosyln Kemp
Immunogenic microenvironment: Associate Professor Alexander McLellan
Melanoma Detection, Screening and Epidemiology
Professor Mark Elwood, Associate Professor Brian Cox, Dr Mary-Jane Sneyd,
Melanoma Treatment, Including Pre-clinical Models and Clinical Trials
Professor Michael Findlay, Dist Professor Bruce Baguley, Professor Rod Dunbar, Professor Ian Hermans, Professor Gavin Painter, Dr Catherine Barrow, Dr Lyndell Kelly,
Melanoma End-of-Life Care Research
Melanoma Health Services and Outcomes Research
Professor Mark Elwood, Mr Jeremy Simcock, Mr Scott Babington,
Melanoma Patient Participation Research
Melanoma Survival Research
New Zealand-Specific Information on Melanoma:
For NZ Patients
- Melanoma Treatment
- Trial Provides Guidance on Lymph Node Surgery in Melanoma
- Personalized Treatment Vaccines for Melanoma
- USA Melanoma risk assessment tool
Standards of Service Provision for Melanoma Patients in New Zealand – Provisional
This provisional melanoma tumour standard describes the level of service that a person with melanoma in New Zealand should have access to. All of the recently developed provisional tumour standards include a number of standard statements that are generic across most cancers; they apply to all people with cancer and to all cancer types.